Abbott Laboratories raised its quarterly dividend to $0.63, marking a 6.8% increase and continuing a streak of 52 years of dividend growth. The company generated $6.35 billion in free cash flow in 2024, with a 60.4% payout ratio.

Medical devices saw a 12.5% growth in Q3 2025 for Abbott, with the FreeStyle Libre product generating $2 billion in quarterly revenue. The company has been systematically reducing debt, with total debt dropping to $12.9 billion by Q3 2025.

Abbott’s CEO prioritized dividend growth on the Q3 earnings call. The company’s diversified revenue streams, declining debt, and 60% free cash flow payout ratio contribute to a very safe dividend safety rating. Abbott is built for investors seeking consistent dividend growth over high current yield.

Read more at Yahoo Finance: Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage